Jade Biosciences, Inc.
JBIO
Last
$14.39
Day
+1.7%
1y
+50.5%
5y
-97.8%
52w
-49.5%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
2026-11-1233d
EMA 21
15.45
EMA 50
17.54
EMA 200
21.32
20d high
-24.9%
5y high
-98.8%
5y range
1th
Positions held
Your positionsJBIO isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-6
Hold
avoid
Signal
Sell
Target
$15.87
Stop
$12.71
Stop distance
11.7%
Target vs last
+10.3%
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
Bull case
- Jade Biosciences operates in the biotechnology sector, which is known for its potential to innovate and address unmet medical needs, attracting significant investor interest.
- The company has a strong current ratio of 14.927, indicating excellent short-term financial health.
- Jade Biosciences has a market cap of approximately $852.84 million, suggesting it has substantial resources for future growth.
Bear case
- The company has reported a consistent net income loss, with -55.765 million in Q2 2026, indicating ongoing financial struggles.
- Jade Biosciences has not generated any revenue in recent quarters, with a total revenue of $0.0 for 2025 and Q1-Q2 of 2026.
- The stock has a strong sell signal with a score of -24.00, reflecting negative market sentiment and technical indicators.
Fundamentals
| Market cap | $899.90M | Enterprise value | $440.09M | Trailing P/E | — | Forward P/E | -5.31 |
| PEG | — | Price / book | 2.04 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | — | ROA | — | Debt / equity | 0.00 |
| Current ratio | 14.93 | Free cash flow | — | Analyst recommendation | strong_buy | Mean target | $50.13 |
| 52w high | $28.00 | 52w low | $8.36 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$55.8M | -$40.4M | -$31.9M | -$25.2M | -$32.1M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$58.9M | -$43.4M | -$35.0M | -$27.4M | -$27.8M | — |
Yearly (6y)
| 2025 | |
|---|---|
| Revenue | $0.0M |
| Op margin | — |
| Net income | -$127M |
| Gross margin | — |
| Gross profit | — |
| Operating income | -$114M |
Headline scan
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-04 · Climb Bio's Phase-1 Data From IgA Nephropathy Trial 'Positive,' Wedbush Says
2026-09-01 · Jade Biosciences to Participate in Upcoming Conferences
2026-08-10 · Wedbush Adjusts Price Target on Jade Biosciences to $47 From $45, Keeps Outperform Rating
2026-08-10 · Jade Biosciences' Q2 Loss Narrows
Price (daily)
Full chart · RSI · MACD · patternsJBIO · daily-15.6% over 13 sessions
Close EMA21 EMA50 EMA200
Quarterly · revenue, net income, margins
Revenue Net income Gross margin Op margin